Clarity initiates phase I/IIa theranostic trial of 64/67Cu SAR-bisPSMA in metastatic CRPC July 29, 2021
Clarity recruits patients with prostate cancer to evaluate PET imaging with [64Cu]SAR-bisPSMA July 19, 2021
New beta-amyloid PET imaging agent [18F]Flotaza shows promise in Alzheimer's disease brain July 7, 2021
Phase I trial shows diagnostic potential of 64Cu-SAR-bombesin PET/CT in patients with breast cancer June 15, 2021
RSS